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Background: Exacerbations of COPD contribute to lung function decline and reduced quality of
life. Treatment of exacerbations in the hospital setting is costly, but information concerning
the component cost drivers of this care is scarce. Our objective was to describe and charac-
terize costs of COPD care in the hospital setting.
Methods: Administrative data from 602 hospitals were used to calculate 2008 costs for COPD-
related emergency department (ED) visits, simple inpatient admissions and complex admis-
sions (categorized as intubation/no intensive care, intensive care/no intubation, or intensive
care/intubation) among COPD patients’ age 40 years. Inpatient mortality, length of stay
(LOS), and readmission rates in 2005e2008 were also calculated.
Results: Mean 2008 costs were $647 (SD $445) for ED visits (n Z 24,617), $7242 ($7987) for
simple admissions (n Z 42,734), and $20,757 ($41,370) for complex admissions (n Z 4142).
Intensive care/intubation admissions incurred the highest costs ($44,909 [SD, $80,351];
n Z 838). Complex admissions accounted for 5.8% of hospital-based COPD care in 2008, but
20.9% of costs. Mean LOS ranged from 4.5 days (SD 3.3) for simple admissions to 16.0 days
(16.7) for intensive care/intubation admissions. Death occurred in 0.9% of simple admissions,
10.3% of all complex admissions, and 26.5e39.1% of admissions involving intubation. Readmis-
sion rates within 30e60 days for ED visits, simple admissions and complex admissions werestructive pulmonary disease; CVD, cardiovascular disease; ED, emergency department; ICD-9-CM,
s, ninth revision, clinical modification; ICS, inhaled corticosteroid; ICU, intensive care unit; IV,
gonist; LOS, length of stay; LRTI, lower respiratory tract infection; SD, standard deviation; URTI,
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Hospital and emergency department costs of COPD 45517.8%, 15.3% and 15.7%, respectively. From 2005 to 2008, trends in LOS were relatively flat;
inflation-adjusted costs increased 4.0e5.9%.
Conclusions: Costs of hospital-based care for COPD are substantial. Admissions involving intu-
bation or intensive care are associated with the highest costs, LOS, and mortality.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a leading
cause of mortality and morbidity worldwide, affecting
approximately 210 million people and leading to 3 million
deaths annually.1 In the United States, COPD is the fourth
leading cause of death and accounts for 15.4million physician
visits, 1.5 million emergency department (ED) visits, and
636,000hospitalizationseachyear.2,3 Basedonnational survey
data, the total economic burden of COPD in the United States
in 2007 was calculated to be $42.6 billion, including $26.7
billion in direct healthcare expenditures, of which $11.3
billion was for hospital care.3,4 The burden of COPD is expec-
ted to increase considerably as the U.S. population ages.5
Patients with COPD experience exacerbations one to
three times a year, with treatment often requiring emer-
gency room care or hospitalization, which contributes
substantially to the financial burden of the disease.6,7
Depending on the population studied, an estimated
25e47% of patients with COPD are hospitalized and as many
as 26% have emergency room visits annually.8,9 Various
observational studies have found that inpatient care
accounts for 52e70% of the direct medical costs of
COPD.10e15 This cost increases with disease severity: inpa-
tient costs of patients with stage III (severe) disease are
double those of patients with stage II (moderate) disease
and 6.5 times greater than those of patients with stage I
(mild) disease.12 Hospitalizations for COPD are also associ-
ated with considerable mortality. Using 1995e1998 data,
Afessa and colleagues reported that the mortality rate
among patients with COPD after admission to an intensive
care unit (ICU) was 15e24%, and this increased to 30% in
patients 65 years of age and older.16
Apart from a study that used 2000e2001 data, there is
a scarcity of literature describing the components and
characteristics of hospital-based care that contribute the
most to medical costs.17 The objective of this study was to
describe, update and characterize costs of COPD hospital-
izations and emergency department (ED) visits and to
examine associated characteristics and trends over time.Methods
We conducted a retrospective, cross-sectional study of
healthcare costs and utilization using hospital administrative
data from the Premier Perspective Database (Premier,
Inc., Charlotte, NC). The database contains de-identified
billing and coding data (diagnoses, procedures, costs, drugs
dispensed, and patient demographic and hospital charac-
teristics) from 602 U.S. not-for-profit acute care hospitals.
The database contains more hospitals in the southern region
of the United States compared to the remainder of the
country, and is populated by fairly equal numbers ofhospitals in the eastern, western and midwestern regions.
Financial data include both billed charges and hospital costs.
Cost data were used in this analysis to more accurately
reflect actual hospital costs.
Study design and criteria
We evaluated outcomes for three categories of utilization:
ED visits, simple inpatient admissions, and complex inpa-
tient admissions (collectively, “encounters”). Encounters
met the following criteria: (1) occurred January 1, 2005
to September 30, 2008, (2) had a primary discharge diag-
nosis of COPD, and (3) the patient was age 40 years
at the time of service. A diagnosis of COPD was identified
by International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) codes for chronic bronchitis
(491.xx), emphysema (492.xx), or unspecified chronic
airway obstruction (496.xx). Encounters with a secondary
diagnosis of respiratory cancer, cystic fibrosis, bronchiec-
tasis, pneumonociosis, pulmonary fibrosis, pulmonary
tuberculosis or sarcoidosis or fibrosis due to tuberculosis
were excluded.
Simple inpatient admissions were defined as those
involving no intubation or intensive care unit (ICU) stay.
Complex admissions involved ICU (general, surgical or
medical ICU) or intubation and were categorized as intu-
bation/no ICU, ICU/no intubation or ICU/intubation based
on ICD-9-CM procedure codes, Current Procedural Termi-
nology (CPT) codes, and charge codes. The cardiac care
unit was not counted when identifying ICU care in order to
ensure that the ICU admissions counted were primarily
attributable to COPD rather than a coronary condition. Only
stand-alone ED visits were counted as ED visits. ED visits
that resulted in an inpatient admission were not included in
the ED category. The latter are readily identifiable in the
Premier dataset using the variable ADM_SOURCE, for which
a value of 7 indicates the admission was from the ED.
Patient demographic variables, including age, sex, and
payor type, were collected for each encounter. To further
characterize patients, a comorbidity score was calculated
for each encounter using the Dartmouth-Manitoba adapta-
tion of the Charlson Comorbidity Index. This algorithm uses
diagnosis codes in claims data to identify the presence or
absence of 19 comorbidities (range of weighted score,
0e33). A higher Charlson score represents a higher burden
of comorbidity and higher risk for one-year mortality. We
excluded codes for COPD from the scoring, since COPD was
the disease of interest.18,19 Additional binary comorbidity
variables (asthma, cardiovascular disease, depression,
lower respiratory tract infection, upper respiratory tract
infection) were created based on secondary diagnosis
codes. Respiratory and non-respiratory drugs dispensed
were identified using standard charge codes. For purposes
of the study, oral corticosteroids and antibiotics dispensed
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Fig. 1 Percentage of total encounters, costs and deaths by
utilization category, 2008.
456 A.A. Dalal et al.were assumed to be for the treatment of COPD and were
included in the respiratory drug category.
Outcomes
Primary outcomes were cost, length of stay (LOS), mortality
at discharge, and readmission rates. To assess readmission
rates, the first COPD-related encounter during the year was
designated the index event and subsequent encounters in
the same or following month were counted as repeat visits/
readmissions; thus follow-up ranged from 30 to 60 days.
However, it was not possible to determine the temporal
order of encounters occurring in the same month from 1/1/
2005 to 6/30/2007 due to absence of a sequencing variable.
This was related to the data variables in the Premier
database and was not under control of the authors.
Therefore, repeat ED visits and readmissions occurring in
the same month as the index event were not counted. Thus,
the readmission rates in 2005, 2006, and the first half of
2007 are underestimated and not directly comparable to
rates in the last half of 2007 and in 2008.
Analysis
For each type of encounter, means were calculated for
medical and pharmacy costs. In analyzing cost trends, costs
in 2005e2007 were adjusted for inflation to 2008 costs using
the Consumer Price Index for medical care (U.S. Depart-
ment of Labor). Mean LOS and mortality rate at discharge
were calculated for inpatient admissions. Rates of read-
mission for ED visits and hospitalizations were also calcu-
lated. Except for readmission rates, which were calculated
at the patient level, all analyses were conducted at the
encounter level. Detailed data are presented for 2008 and
summary data for 2005e2008. Counts and percentages are
presented for categorical variables and means  SD (stan-
dard deviation) for continuous variables. Inferential
statistical testing was not performed since comparisons
between groups of patients or between categories of
healthcare utilization were not made; our aim was simply
to describe the costs and characteristics of the healthcare
utilization events. Statistical analyses were conducted
using SAS version 9.1.3 (SAS Institute; Cary, NC, USA). All
authors had full access to all the data and take responsi-
bility for the integrity of the data and accuracy of the data
analysis.
Results
A total of 71,493 encounters in 2008 met inclusion criteria.
Of these, 28.7% were ED visits, 49.8% were simple inpatient
admissions, and 4.8% were complex inpatient admissions
(Fig. 1). The majority of complex admissions involved ICU
care without intubation (72.7%, n Z 3015). More than half
of ED visits and inpatient admissions occurred in females
(56.4%) and patients who were 65 years of age or older
(59.3%) (Table 1). Mean bed size of the hospitals was 373
and 30.3% of encounters occurred in teaching hospitals.
The highest mean Charlson comorbidity score was asso-
ciated with complex admissions involving intubation/no ICU
(2.13 [SD, 1.87]). The most prevalent concomitantcondition in all encounters combined was cardiovascular
disease (51.0%), followed by depression (19.2%), lower
respiratory tract infection (13.7%), upper respiratory tract
infection (3.3%) and asthma (1.6%). Cardiovascular disease
was present more often among simple and complex
admissions (64.8% and 78.1%, respectively) than among ED
visits (22.5%). Among complex admissions, lower respira-
tory tract infection was the second most prevalent
concomitant condition (27.8%) and it was particularly
prevalent among ICU/intubation admissions (40.6%). The
most prevalent payor source was Medicare (66.4% of all
encounters).
Utilization and costs
Mean LOS was nearly twice as long for complex admissions
as for simple admissions (8.8 days vs. 4.5 days) (Table 2).
Among complex admissions, those involving intubation had
the highest LOS: 10.9 and 16.0 days for intubation/no ICU
admissions and ICU/intubation admissions, respectively,
compared to 6.6 days for ICU admissions without intuba-
tion. Table 2 shows that the cost of complex admissions was
nearly three times higher than the cost of simple admissions
($20,757 vs. $7987). Among complex admissions, those
involving intubation had substantially higher costs than
those not involving intubation: $29,530 and $44,909 for
ICU/intubation and intubation/no ICU admissions respec-
tively, compared to $13,203 for ICU/no intubation admis-
sions. The majority of intubation/no ICU admissions
involved a cardiac care unit stay, and this may explain much
of the higher costs in this category. Medications accounted
for 11.0% of simple inpatient admission costs and 14.4% of
complex admissions costs, compared to 6.3% of ED costs.
Respiratory medications. Respiratory medications
accounted for 22.1% of total medication costs and
antibiotics accounted for approximately 74.3% of respira-
tory medication costs (data not shown). The percentage of
encounters in which respiratory and non-respiratory medi-
cations were dispensed is shown in Table 3. Oral/intrave-
nous corticosteroids were the most common class of
respiratory medications dispensed (76.8% of all encoun-
ters), followed by antibiotics (64.8%) and the short-term
anti-cholinergic ipratropium (51.9%).
Controller medications for COPD were dispensed in
approximately 1% of ED visits and 10e30% of inpatient
admissions. During simple and complex admissions, the
Table 1 Demographic characteristics by encounter category in 2008.a
All encounters
N Z 71,493
Emergency
department N Z 24,617
Simple inpatient
admission N Z 42,734
Complex inpatient
admissionb N Z 4142
Age in years (mean, SD) 67.5 (12.3) 64.0 (12.5) 69.4 (11.8) 68.9 (11.2)
Female 40,287 (56.4) 13,568 (55.1) 24,426 (57.2) 2293 (55.4)
Charlson comorbidity
index (mean, SD)
1.05 (1.45) 0.39 (0.76) 1.36 (1.57) 1.79 (1.80)
Payor
Medicare 47,494 (66.4) 13,883 (56.4) 30,644 (71.7) 2967 (71.6)
Medicaid 7420 (10.4) 3515 (14.3) 3528 (8.3) 377 (9.1)
Commercial 10,161 (14.2) 3738 (15.2) 5860 (13.7) 563 (13.6)
Self-pay 4048 (5.7) 2582 (10.5) 1348 (3.2) 118 (2.9)
Other 2379 (3.3) 899 (3.7) 1354 (3.2) 117 (2.8)
Concomitant conditions
Asthma 1143 (1.6) 423 (1.7) 673 (1.6) 47 (1.1)
CVD 36,376 (51.0) 5538 (22.5) 27,702 (64.8) 3236 (78.1)
Depression 13,695 (19.2) 1332 (5.4) 11,257 (26.3) 1106 (26.7)
LRTI 9770 (13.7) 881 (3.6) 7739 (18.1) 1150 (27.8)
URTI 2393 (3.3) 710 (2.9) 1566 (3.7) 117 (2.8)
Hospital
Geographic region
East 10,271 (14.4) 2012 (8.2) 7585 (17.8) 674 (16.3)
Midwest 13,374(18.7) 3965 (16.1) 8550 (20.0) 859 (20.7)
South 35,800 (50.1) 12,796 (52.0) 21,023 (49.2) 1981 (47.8)
West 12,048 (16.9) 5844 (23.7) 5576 (13.1) 628 (15.2)
Bed size (SD) 373.0 (216.0) 343.0 (208.2) 388.6 (216.2) 391.2 (240.1)
Teaching status (SD) 21,628 (30.3) 6312 (25.6) 13,962 (32.7) 1354 (32.7)
CVD, cardiovascular disease; LRTI, lower respiratory tract infection; URTI, upper respiratory tract infection.
a All values are n (%) unless otherwise specified.
b Admission involving ICU stay and/or intubation.
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inhaled corticosteroid plus long-acting beta-adrenergic
agonist combination (31.3% and 32.1%simplecomplex,
respectively), long-acting anti-cholinergic (26.4% and
29.9%) and inhaled corticosteroid (10.6% and 13.2%).
Mortality
Of 828 deaths at discharge in 2008 (1.8% of encounters),
2.3% were associated with ED visits, 46.1% with simple
admissions, and 51.3% with complex inpatient admissions
(Fig. 1). A discharge status of death was documented in
0.9% of simple inpatient admissions and 10.3% of all
complex admissions combined (data not shown). However,Table 2 Cost and length of stay for emergency department vis
Encounter type, (N) Mean cost (SD), $US
Medical Pha
Emergency department
visits (24,617)
$606 ($379) $41
Simple admission (42,734) $6,444 ($7,086) $79
Complex admission, any (4,142) $18,458 ($36,423) $2,
Intubation, no ICU (289) $26,336 ($37,983) $3,
ICU, no intubation (3,015) $11,836 ($11,289) $1,
ICU þ intubation (838) $39,566 ($70,587) $5,
All encounters (71,493) $5,130 ($11,192) $62death occurred in 26.5% of ICU/intubation admissions and
39.1% of intubation/no ICU admissions.
Readmissions
Readmission rates in 2008 among patients with an initial
COPD-related ED visit, simple admission, or complex admis-
sion were 17.8%, 15.3% and 15.7%, respectively (Table 4).
Trends over time
Between 2005 and 2008, the mean cost of an ED visit,
adjusted for inflation, increased by 4.0% and the cost of
a simple admission increased by 5.9% (Fig. 2). There wasits and inpatient admissions in 2008.
Length of stay in
days, mean (SD)rmacy Total
($113) $647 (445) e
8 ($1,211) $7,242 ($7,987) 4.5 (3.3)
299 ($5,579) $20,757 ($41,370) 8.8 (10.1)
194 ($5,056) $29,530 ($42,491) 10.9 (11.0)
368 ($1,722) $13,203 ($12,623) 6.6 (5.6)
343 ($11,037) $44,909 ($80,351) 16.0 (16.7)
4 ($1,727) $5,754 ($12,676) 4.8 (4.5)
Table 3 Medications administered to COPD patients by encounter type.
Medication category Emergency department
visits N Z 24,617
Simple inpatient
admissions,
N Z 42,734
Complex inpatient admissions
Intubation/no
ICU N Z 289
ICU/no intubation
N Z 3015
ICU þ intubation
N Z 838
Percentage of encounters in which medication was dispensed
Any medication 87.8 99.9 100.0 100.0 100.0
Non-respiratory 70.8 99.7 100.0 100.0 100.0
Respiratory:
Oral/IV corticosteroid 56.6 87.2 88.6 89.9 93.7
Short-acting b-antagonist 16.5 27.8 35.0 29.3 44.3
LABA 0.0 3.8 3.8 5.4 3.8
Short-acting anti-cholinergic 39.9 58.0 68.9 55.9 68.9
Long-acting anti-cholinergic 0.1 26.4 25.3 30.2 30.8
ICS 0.7 10.6 13.5 11.5 19.1
ICS þ LABA combination 0.2 31.3 26.6 32.4 33.2
Short-acting anti-cholinergic
þ b-agonist combination
14.1 20.8 28.7 20.4 47.6
Theophylline/methylxanthine 0.1 7.5 11.4 10.4 15.5
Antibiotic 26.7 84.6 88.9 86.0 90.6
ICS, inhaled corticosteroid; LABA, long-acting beta-agonist.
458 A.A. Dalal et al.little change in cost of a complex admission (all types
combined) across years. Lengths of stay for simple admis-
sions and complex admissions did not change substantially
from 2005 to 2008 (Fig. 3). Readmission rates in 2005e2008
are shown in Fig. 4; the lower rates in 2005e2007 may be
due to lack of complete data capture in those years.
Discussion
In this study, we identified the direct healthcare costs of
COPD treatment in the hospital setting, including ED visits,
simple admissions (without intubation or ICU), and complex
admissions (with intubation and/or ICU), using administra-
tive data from 602 US hospitals. Several prior studies have
calculated mean costs of inpatient care at the population
level, with the mean cost representing patients with andTable 4 Rates of repeat emergency department visits and
inpatient readmissions in 2008.
Index eventa (N) Patients with repeat
emergency department
visit or readmission,b N (%)
Repeat ED visit
COPD-related
ED visit (19,304)
3442 (17.8)
Readmission
COPD-related
simple admission
(35,107)
5370 (15.3)
COPD-related complex
admissionc (3429)
537 (15.7)
a First chronologically occurring event in 2008 with a primary
diagnosis of COPD.
b Subsequent events with any primary diagnosis occurring
within 30e60 days.
c Admission involving ICU and/or intubation.without admissions during the study period. However, we
performed the analysis at the encounter level to calculate
the mean cost of the events, and we examined admissions
requiring different levels of care in order to better under-
stand key drivers of overall costs in the hospital setting.
We observed a mean cost of $7242 for simple COPD
admissions and $20,757 for complex admissions in 2008. The
highest cost admissions were those requiring intensive care
and intubation ($44,909), and intubation may be a marker
for severity of illness that increases both cost and LOS. In
2008, complex admissions accounted for only 5.8% of
hospital-based utilization for COPD, but 20.9% of costs.
Stanford and colleagues, using similar methods and
2000e2001 cost data, reported means of $5997 ($8003 in
2008 dollars) for simple admissions, $16,428 ($21,924 in
2008 dollars) for complex admissions, and $36,743 ($49,035
in 2008 dollars) for complex admissions involving both
intensive care and intubation.17
From 2005 to 2008, costs of emergency department visits
and simple admissions increased modestly. Both mortality
and LOS were highest for admissions involving intubation,
which is not unexpected. It has been shown that exacer-
bations tend to cluster together in time.20 In this study,
over 15% of patients hospitalized for COPD in 2008 were
readmitted with any diagnosis within 30e60 days and 17.8%
of ED patients had a repeat ED visit with any diagnosis
within 30e60 days. Other studies have reported an all-
cause readmission rate among COPD patients of 22.6%
within 30 days and a COPD-related readmission rate of 38%
within 5 months.21,22
Although we did not evaluate the impact of comorbid-
ities on healthcare utilization and cost, a substantial
proportion of encounters involved patients with comorbid-
ities, including cardiovascular disease, depression and
asthma. The presence of comorbidities may increase the
cost of hospitalizations; for example, patients with
comorbid COPD and asthma have significantly higher
respiratory-related healthcare costs than patients with
AB
$552 $586 $610 $647
$18,805 $19,316 $19,236
$20,757
$6,068
$7,242$6,750$6,459
$0
$5,000
$10,000
$15,000
$20,000
$25,000
2005 2006 2007 2008
Emergency Department Simple inpatient admissions Complex inpatient admissions
$24,585 $26,616
$29,982 $29,530
$41,113
$44,712 $45,600 $44,909
$13,203$14,169$14,282 $14,947
$0
$10,000
$20,000
$30,000
$40,000
$50,000
2005 2006 2007 2008
Intubation/No ICU ICU/No Intubation ICU + Intubation
Fig. 2 a and b. Mean cost of emergency department visits,
simple and complex admissions, and subcategories of complex
admissions, 2005e2008.
13.9% 
17.8% 
10.8% 10.6% 10.3% 
15.3% 
12.6% 
10.7% 
15.7% 
12.4% 
10.7% 10.5% 
0% 
4% 
8% 
12% 
16% 
20% 
200 5 200 6 200 7 200 8 
ED Simple inpatient admissions Complex inpatient admissions 
Fig. 4 Rates of repeat emergency department visits and
inpatient readmissions, 2005e2008. Rates in 2005 through first
half of 2007 are based on encounters in the month following
the index event month; rates in last half of 2007 and in 2008
are based on encounters in the index event month (post-index
event) and the following month.
Hospital and emergency department costs of COPD 459COPD alone.23,24 This study evaluated unadjusted costs for
ED visits and admissions. If costs were adjusted using
multivariate analysis, the primary variable expected to
drive costs would be disease severity. In fact, study cohorts
have often been defined in terms of disease severity using
these same encounters (ED visits, hospital admissions, and
hospital admissions with or without intubation/ICU) as
a marker or proxy for disease severity, and an analysis that
controls for variables that significantly affect costs would
not be expected to produce quantitatively different
results.
This study has some important advantages. Costs of
treating chronic disease are seldom examined from the
hospital perspective, as most studies use administrative
data containing charges billed to third party payors, which
may be more or less than actual costs. This study sheds light4.6 4.5 4.4 4.5
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Fig. 3 Mean length of stay for simple and complex inpatient
admissions, 2005e2008.on actual costs incurred by hospitals. Another strength is
the large sample size of the encounter categories. This
study has some limitations as well. The data were obtained
from a large database comprising inpatient data from 6022
hospitals. A limitation of this database is that unique
patients can be identified only within the records of a given
hospital and not across different hospitals. Thus, if patients
were readmitted to a different hospital, we were unable to
capture the readmission. In addition, we were unable to
capture readmissions to the same hospital that occurred in
the month of the initial hospitalization for January 2005
through June 2007 due to lack of an encounter sequencing
variable. Jencks et al found that 24% of Medicare patients
initially admitted to a large hospital for any reason were
readmitted to a different hospital within 30 days.21 Given
these limitations, the rates of readmission and repeat ED
visits reported here are undoubtedly underestimated to
a certain degree. Because this database contained no
clinical data, we were unable to determine disease severity
based on spirometry or other clinical measures, nor could
we determine smoking status. We also had no information
on patient treatment regimens prior to hospitalization, so
could not characterize encounters with respect to the
patient’s maintenance COPD drug therapy. Although
the Premier database contains hospitals in all regions of the
United States, it contains proportionately more hospitals in
the southern region. Thus, the findings may not be repre-
sentative of all regions in the country nor of the country as
a whole. Finally, administrative databases may contain
errors related to diagnosis codes and procedures.
Conclusions
Prior studies have indicated that hospitalizations account
for 52e70% of direct healthcare costs for COPD.10e15 The
findings reported here serve to update, characterize and
underscore the financial burden of COPD treatment in the
hospital setting. We found that admissions involving intu-
bation or intensive care were associated with the highest
costs, greatest LOS, and highest mortality. Moreover,
hospital-based costs of treating COPD have not decreased
460 A.A. Dalal et al.over time. In fact, costs of ED visits and simple admissions
have increased modestly in recent years. In addition,
a substantial fraction of patients receiving hospital-based
care for COPD are readmitted or have repeat ED visits
within a short period of time. These findings are particu-
larly relevant given that COPD is progressive in nature,
exacerbations often require ED and inpatient care, and
newer treatment regimens that reduce exacerbations are
available.7,25,26
Acknowledgements
AAD participated in study design and interpretation of
results; AOD, PR and MS participated in study design, data
collection, statistical analysis, and interpretation of
results. All authors participated in drafting and revising the
manuscript. Judith S. Hurley, Hurley Health and Medical
Communications, provided medical writing services, for
which GlaxoSmithKline provided financial compensation.Financial support
nancial support for this study was provided by
axoSmithKline.Fi
GlConflict of interest statement
AAD is an employee of GlaxoSmithKline (GSK) and owns
company stock. AOD and MS are employees of Xcenda,
which has received research funds from GSK. PR reports no
conflicts of interest. The study sponsor was not involved in
study design, data collection, or analysis beyond the
involvement of AAD as a study investigator. The sponsor was
provided the opportunity to review the manuscript prior to
publication, but final decisions as to content were the sole
responsibility of the authors.
References
1. World Health Organization. Chronic obstructive pulmonary
disease. Geneva: WHO, www.who.int/mediacentre/
factsheets/fs315/en/; 2009. Fact Sheet no. 315. URL:.
2. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive
pulmonary disease surveillancedUnited States, 1971e2000.
MMWR Surveill Summ 2002;51:1e16.
3. National Heart, Lung and Blood Institute. Morbidity and
mortality: 2007 chartbook on cardiovascular, lung, and blood
diseases. Bethesda, MD: U.S. Department of Health and Human
Services; 2007.
4. Chronic obstructive pulmonary disease (COPD) fact sheet.
Washington, DC: American Lung Association, http://www.
lungusa.org/lung-disease/copd/resources/facts-figures/COPD-
Fact-Sheet.html; 2009. URL:.
5. National Institutes of Health, National Heart, Lung, and Blood
Institute. Global strategy for the diagnosis, management, and
prevention of chronic obstructive pulmonary disease.
NHLBI/WHO Workshop; 2004.
6. Seemungal TA, Donaldson GC, Bhowmik, et al. Time course and
recovery of exacerbations in patients with chronic obstructivepulmonary disease. Am J Respir Crit Care Med 2000;161:
1608e13.
7. Strassels SA, Smith DH, Sullivan SD, et al. The costs of treating
COPD in the United States. Chest 2001;119:344e52.
8. Mapel DW, Hurley JS, Frost FJ, et al. Health care utilization in
chronic obstructive pulmonary disease. A case-control study in
a health maintenance organization. Arch Intern Med 2000;160:
2653e8.
9. Menzin J, Boulanger L, Marton J, et al. Economic burden of
chronic obstructive pulmonary disease in a Medicare pop-
ulation. Respir Med 2008;102:1248e56.
10. Foster TS, Miller JD, Marton JP, et al. Assessment of the
economic burden of COPD in the U.S.: a review and synthesis of
the literature. COPD 2006;3:211e8.
11. Halpern MT, Stanford RH, Borker R. The burden of COPD in the
U.S.A.: results from the Confronting COPD Survey. Respir Med
2003;97(Suppl. C):81e9.
12. Hilleman DE, Dewan N, Malesker M, et al. Pharmacoeconomic
evaluation of COPD. Chest 2000;118:1278e85.
13. Marton JP, Boulanger L, Friedman M, et al. Assessing the costs
of chronic obstructive pulmonary disease: the state Medicaid
perspective. Respir Med 2006;100:996e1005.
14. Miller JD, Foster T, Boulanger L, et al. Direct costs of COPD in
the U.S.: an analysis of medical expenditure panel survey
(MEPS) data. COPD 2005;2:311e8.
15. Stuart B, Doshi JA, Briesacher B, et al. Impact of prescription
coverage on hospital and physician costs: a case study of
Medicare beneficiaries with chronic obstructive pulmonary
disease. Clin Ther 2004;26:1688e99.
16. Afessa B, Morales IJ, Scanlon PD, et al. Prognostic factors,
clinical course, and hospital outcome of patients with chronic
obstructive pulmonary disease admitted to an intensive care
unit for acute respiratory failure. Crit Care Med 2002;30:
1610e5.
17. Stanford RH, Shen Y, McLaughlin T. Cost of chronic obstructive
pulmonary disease in the emergency department and hospital.
Treat Respir Med 2006;5:343e9.
18. Charlson ME, Pompei P, Ales KL, et al. A new method of clas-
sifying prognostic comorbidity in longitudinal studies: devel-
opment and validation. J Chronic Dis 1987;40:373e83.
19. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity
index for use with ICD-9-CM administrative data: differing
perspectives. J Clin Epidemiol 1993;46:1075e9.
20. Hurst JR, Donaldson GC, Quint TK, et al. Temporal clustering of
exacerbations in chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2009;179:369e74.
21. Jencks SF, Williams MV, Coleman EA. Rehospitalization among
patients in the Medicare fee-for-service program. N Engl J Med
2009;360:1418e28.
22. Bahadori K, FitzGerald JM, Levy RD, et al. Risk factors and
outcomes associated with chronic obstructive pulmonary
disease exacerbations requiring hospitalizations. Can Respir J
2008;16:e43e9.
23. Blanchette CM, Broder M, Ory C, et al. Cost and utilization of
COPD and asthma among insured adults in the US. Curr Med Res
Opin 2009;25:1385e92.
24. Shaya FT, Dongyi D, Akazawa MO, et al. Burden of concomitant
asthma and COPD in a Medicaid population. Chest 2008;134:
14e9.
25. Celli BR, MacNee W. ATS/ERS Task Force. Standards for the
diagnosis and treatment of patients with COPD: a summary of
the ATS/ERS position paper. Eur Respir J 2004;23:932e46.
26. Global Initiative for Chronic Obstructive Lung Disease. Global
strategy for diagnosis, management and prevention of COPD.
Gig Harbor, WA: Medical Communications Resources, Inc.,
www.goldcopd.com; December 2009. URL:.
